FRANKLIN LAKES, N.J.,
Dec. 22, 2017 /PRNewswire/ -- BD
(Becton, Dickinson and Company) (NYSE: BDX), a leading global
medical technology company, issued the following statement
regarding today's clearance by the U.S. Federal Trade Commission
(FTC) for BD to acquire C. R. Bard (NYSE: BCR), contingent on the
divestitures of BD's soft tissue core needle biopsy product line
and C. R. Bard's Aspira® product line of tunneled home drainage
catheters and accessories:
"FTC approval brings us one step closer to full regulatory
clearance of the Bard acquisition," said Vincent A. Forlenza, chairman and CEO of BD. "We
currently expect that the Bard acquisition will close in December,
pending approval by the Ministry of Commerce of the People's Republic of China (MOFCOM) and
the satisfaction of customary closing conditions."
About BD
BD is a global medical technology company
that is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. BD leads in
patient and health care worker safety and the technologies that
enable medical research and clinical laboratories. The company
provides innovative solutions that help advance medical research
and genomics, enhance the diagnosis of infectious disease and
cancer, improve medication management, promote infection
prevention, equip surgical and interventional procedures, and
support the management of diabetes. The company partners with
organizations around the world to address some of the most
challenging global health issues. BD has nearly 50,000 associates
across 50 countries who work in close collaboration with customers
and partners to help enhance outcomes, lower health care delivery
costs, increase efficiencies, improve health care safety and expand
access to health. For more information on BD, please visit
bd.com.
FORWARD-LOOKING STATEMENTS
This press release
contains "forward-looking statements" within the meaning of the
federal securities laws, including Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, related to the pending acquisition of Bard
by BD that involves substantial risks and uncertainties, including,
among other things, risks related to the satisfaction of the
conditions to closing the acquisition in the anticipated timeframe
or at all. These statements are based on the current expectations
of BD management and these statements speak only as of the date of
this document. BD undertakes no obligation to update any
forward-looking statements to reflect events or circumstances after
the date hereof, except as required by applicable laws or
regulations.
Contacts:
|
|
|
|
Troy
Kirkpatrick
|
Monique N.
Dolecki
|
BD Public
Relations
|
BD Investor
Relations
|
858.617.2361
|
201.847.5378
|
troy.kirkpatrick@bd.com
|
Monique_Dolecki@bd.com
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/bd-statement-on-ftc-clearance-of-bard-acquisition-300575094.html
SOURCE BD (Becton, Dickinson and Company)